+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Urothelial Cancer Drugs Market by Therapy Type (Antibody Drug Conjugates, Chemotherapy, Immunotherapy), Mechanism (FGFR Inhibitors, Nectin-4 Targeted, PD-1 Inhibitors), Line Of Therapy, Stage, Administration Route, Treatment Setting - Global Forecast 2025-2030- Product Image
Urothelial Cancer Drugs Market by Therapy Type (Antibody Drug Conjugates, Chemotherapy, Immunotherapy), Mechanism (FGFR Inhibitors, Nectin-4 Targeted, PD-1 Inhibitors), Line Of Therapy, Stage, Administration Route, Treatment Setting - Global Forecast 2025-2030- Product Image
Sale

Urothelial Cancer Drugs Market by Therapy Type (Antibody Drug Conjugates, Chemotherapy, Immunotherapy), Mechanism (FGFR Inhibitors, Nectin-4 Targeted, PD-1 Inhibitors), Line Of Therapy, Stage, Administration Route, Treatment Setting - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 182 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5889233
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Urothelial Cancer Drugs Market is experiencing accelerated development, driven by advances in immunotherapy, targeted therapies, and evolving clinical standards. Senior decision-makers require up-to-date intelligence to capitalize on emerging therapeutic trends, address regulatory complexities, and navigate competitive dynamics effectively.

Market Snapshot: Urothelial Cancer Drugs Market

The Urothelial Cancer Drugs Market expanded from USD 3.47 billion in 2024 to USD 3.82 billion in 2025 and is forecasted to reach USD 6.14 billion by 2030, registering a CAGR of 9.95%. These growth patterns highlight ongoing innovation, investment, and demand for advanced urothelial cancer therapies among global stakeholders.

Scope & Segmentation

This report delivers comprehensive insights into the global landscape for urothelial cancer therapies, with a focus on evolving treatment modalities, pipeline innovation, and stakeholder impact across all major regions.

  • Therapy Types: Antibody drug conjugates (including nectin-4 targeted agents), chemotherapy (platinum and non-platinum based), immunotherapies (PD-1 and PD-L1 inhibitors), and targeted therapies (FGFR inhibitors).
  • Mechanisms: PD-1 and PD-L1 inhibition, nectin-4 targeting (such as enfortumab vedotin), and FGFR-directed interventions (including erdafitinib).
  • Lines of Therapy: First, second, and third line or later, reflecting clinical stage progression and sequencing strategies.
  • Clinical Stages: Metastatic, muscle-invasive, and non-muscle invasive urothelial cancer.
  • Administration Routes: Intravenous and oral delivery options, supporting varied care settings.
  • Treatment Settings: Hospital infusion centers, oncology clinics, and outpatient environments.
  • Geographic Coverage: Americas (with detailed country breakdowns), Europe, Middle East & Africa, and Asia-Pacific, considering regional drivers and access models.
  • Company Coverage: Merck & Co., Inc., Roche Holding AG, AstraZeneca PLC, Bristol-Myers Squibb Company, Pfizer Inc., Merck KGaA, Johnson & Johnson, Astellas Pharma Inc., Seagen Inc., and Gilead Sciences, Inc.

Key Takeaways for Senior Leaders

  • Therapeutic innovation in antibody drug conjugates and checkpoint inhibitors is reshaping outcomes, particularly in advanced and resistant disease settings.
  • Growing reliance on multiplex biomarker strategies is optimizing patient stratification and enhancing personalized treatment pathways.
  • Collaboration among pharmaceutical, diagnostic, and contract research organizations is shortening development cycles and supporting faster global launches.
  • Competition continues to shift, with targeted therapies and next-generation technology platforms prompting portfolio diversification among industry leaders.
  • Real-world evidence is gaining influence over regulatory approval, reimbursement decisions, and long-term market positioning.
  • Regional adoption varies, requiring tailored approaches to access, pricing models, and stakeholder engagement in high-growth and emerging markets.

Tariff Impact: Navigating Cost and Supply Chain Disruption

Recent US tariff policy adjustments in 2025 have raised input costs for both active ingredients and finished urothelial cancer therapies. Manufacturers now seek to mitigate expenses through vertical integration and domestic production. These measures, paired with strategic responses such as leveraging free-trade zones and implementing dynamic pricing, are reshaping procurement, reimbursement negotiations, and formulary strategies across global supply chains. Ongoing manufacturer-trade association dialogues, regulatory engagement, and investment in digital supply chain transparency remain central to sustaining market resilience.

Methodology & Data Sources

This research leverages a mixed-methods approach, combining in-depth primary stakeholder interviews with exhaustive secondary evidence from clinical trials, regulatory filings, industry briefings, and financial disclosures. Quantitative analytics benchmark development trends, while expert panel validation ensures data quality and contextual relevance to the urothelial cancer drugs market.

Why This Report Matters

  • Enables actionable decision-making by mapping the evolving landscape of clinical innovations, regulatory changes, and competitive dynamics.
  • Supports planning and investment through granular segmentation, providing visibility into technology, therapy, and regional opportunities.
  • Equips leaders to anticipate and adapt to pricing, supply chain, and policy changes in real time, strengthening business continuity.

Conclusion

This report provides an authoritative analysis of the urothelial cancer drugs market, synthesizing primary and secondary data into clear, executive-level intelligence. Stakeholders gain the insight required to navigate complexity, maximize clinical impact, and secure sustainable commercial growth.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rapid adoption of FGFR inhibitors in patients with FGFR3-mutant urothelial carcinoma following biomarker-driven treatment algorithms
5.2. Expansion of antibody-drug conjugates targeting nectin-4 and HER2 in refractory bladder cancer populations undergoing novel combination regimens
5.3. Integration of emerging immunotherapy agents including PD-1/L1 checkpoint inhibitors in frontline maintenance strategies for advanced urothelial carcinoma
5.4. Development of bispecific T cell engagers enhancing immune synapse formation in BCG-unresponsive non-muscle invasive bladder cancer
5.5. Increasing focus on oral small molecule inhibitors addressing resistance mechanisms in platinum-refractory metastatic urothelial carcinoma
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Urothelial Cancer Drugs Market, by Therapy Type
8.1. Introduction
8.2. Antibody Drug Conjugates
8.2.1. Nectin-4 Targeted
8.3. Chemotherapy
8.3.1. Non Platinum Based
8.3.2. Platinum Based
8.4. Immunotherapy
8.4.1. PD-1 Inhibitors
8.4.1.1. Nivolumab
8.4.1.2. Pembrolizumab
8.4.2. PD-L1 Inhibitors
8.4.2.1. Atezolizumab
8.4.2.2. Durvalumab
8.5. Targeted Therapy
8.5.1. FGFR Inhibitors
9. Urothelial Cancer Drugs Market, by Mechanism
9.1. Introduction
9.2. FGFR Inhibitors
9.2.1. Erdafitinib
9.3. Nectin-4 Targeted
9.3.1. Enfortumab Vedotin
9.4. PD-1 Inhibitors
9.4.1. Nivolumab
9.4.2. Pembrolizumab
9.5. PD-L1 Inhibitors
9.5.1. Atezolizumab
9.5.2. Durvalumab
10. Urothelial Cancer Drugs Market, by Line Of Therapy
10.1. Introduction
10.2. First Line
10.3. Second Line
10.4. Third Line Or Later
11. Urothelial Cancer Drugs Market, by Stage
11.1. Introduction
11.2. Metastatic
11.3. Muscle Invasive
11.4. Non Muscle Invasive
12. Urothelial Cancer Drugs Market, by Administration Route
12.1. Introduction
12.2. Intravenous
12.3. Oral
13. Urothelial Cancer Drugs Market, by Treatment Setting
13.1. Introduction
13.2. Hospital Infusion
13.3. Oncology Center
13.4. Outpatient Clinic
14. Americas Urothelial Cancer Drugs Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Urothelial Cancer Drugs Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Urothelial Cancer Drugs Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Merck & Co., Inc.
17.3.2. Roche Holding AG
17.3.3. AstraZeneca PLC
17.3.4. Bristol-Myers Squibb Company
17.3.5. Pfizer Inc.
17.3.6. Merck KGaA
17.3.7. Johnson & Johnson
17.3.8. Astellas Pharma Inc.
17.3.9. Seagen Inc.
17.3.10. Gilead Sciences, Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. UROTHELIAL CANCER DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY MECHANISM, 2024 VS 2030 (%)
FIGURE 8. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY MECHANISM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY STAGE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2030 (%)
FIGURE 16. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC UROTHELIAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC UROTHELIAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. UROTHELIAL CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. UROTHELIAL CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. UROTHELIAL CANCER DRUGS MARKET: RESEARCHAI
FIGURE 28. UROTHELIAL CANCER DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 29. UROTHELIAL CANCER DRUGS MARKET: RESEARCHCONTACTS
FIGURE 30. UROTHELIAL CANCER DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. UROTHELIAL CANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY NECTIN-4 TARGETED, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY NECTIN-4 TARGETED, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY NON PLATINUM BASED, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY NON PLATINUM BASED, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PLATINUM BASED, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PLATINUM BASED, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY DURVALUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ERDAFITINIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ERDAFITINIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY NECTIN-4 TARGETED, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY NECTIN-4 TARGETED, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ENFORTUMAB VEDOTIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ENFORTUMAB VEDOTIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY NECTIN-4 TARGETED, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY NECTIN-4 TARGETED, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY DURVALUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY THIRD LINE OR LATER, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY THIRD LINE OR LATER, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY METASTATIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY METASTATIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY MUSCLE INVASIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY MUSCLE INVASIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY NON MUSCLE INVASIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY NON MUSCLE INVASIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY HOSPITAL INFUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY HOSPITAL INFUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ONCOLOGY CENTER, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ONCOLOGY CENTER, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY OUTPATIENT CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY OUTPATIENT CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY NECTIN-4 TARGETED, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY NECTIN-4 TARGETED, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 163. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY NECTIN-4 TARGETED, 2018-2024 (USD MILLION)
TABLE 164. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY NECTIN-4 TARGETED, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 167. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 168. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 169. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 170. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 171. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 172. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 173. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 174. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 175. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 176. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 177. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 178. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 179. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 180. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 181. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
TABLE 182. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2030 (USD MILLION)
TABLE 183. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 184. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 185. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 186. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 187. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 188. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 189. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 190. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 191. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 192. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 193. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 194. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 195. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 196. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 197. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY NECTIN-4 TARGETED, 2018-2024 (USD MILLION)
TABLE 198. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY NECTIN-4 TARGETED, 2025-2030 (USD MILLION)
TABLE 199. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 200. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 201. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 202. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 203. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 204. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 205. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 206. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 207. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 208. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 209. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 210. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 211. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 212. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 213. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
TABLE 214. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2030 (USD MILLION)
TABLE 215. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 216. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 217. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 218. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 219. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 220. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 221. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 222. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 223. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 224. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 225. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 226. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 227. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 228. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 229. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY NECTIN-4 TARGETED, 2018-2024 (USD MILLION)
TABLE 230. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY NECTIN-4 TARGETED, 2025-2030 (USD MILLION)
TABLE 231. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 232. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 233. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 234. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 235. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 236. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 237. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 238. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 239. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 240. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 241. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 242. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 243. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 244. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 245. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
TABLE 246. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2030 (USD MILLION)
TABLE 247. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 248. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 249. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 250. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 251. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 252. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 253. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 254. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 255. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 256. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 257. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 258. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 259. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 260. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 261. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY NECTIN-4 TARGETED, 2018-2024 (USD MILLION)
TABLE 262. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY NECTIN-4 TARGETED, 2025-2030 (USD MILLION)
TABLE 263. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 264. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 265. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 266. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 267. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 268. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 269. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 270. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 271. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 272. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 273. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 274. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 275. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 276. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 277. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
TABLE 278. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2030 (USD MILLION)
TABLE 279. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 280. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 281. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 282. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 283. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 284. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 285. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 286. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 287. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 288. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 289. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 290. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 291. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 292. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 293. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY NECTIN-4 TARGETED, 2018-2024 (USD MILLION)
TABLE 294. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY NECTIN-4 TARGETED, 2025-2030 (USD MILLION)
TABLE 295. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 296. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 297. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 298. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 299. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 300. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 301. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 302. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 303. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 304. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 305. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 306. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 307. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 308. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 309. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
TABLE 310. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2030 (USD MILLION)
TABLE 311. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 312. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 313. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 314. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 315. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 316. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 317. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 318. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 319. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 320. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 32

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Urothelial Cancer Drugs market report include:
  • Merck & Co., Inc.
  • Roche Holding AG
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Merck KGaA
  • Johnson & Johnson
  • Astellas Pharma Inc.
  • Seagen Inc.
  • Gilead Sciences, Inc.

Table Information

Report AttributeDetails
No. of Pages182
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 3.82 Billion
Forecasted Market Value ( USD ) by 2030 $ 6.14 Billion
Compound Annual Growth Rate9.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Urothelial Cancer Drugs - Global Strategic Business Report - Product Image

Urothelial Cancer Drugs - Global Strategic Business Report

  • Report
  • 126 Pages
  • Global
From
Urothelial Cancer Drugs Market Report 2025 - Product Image

Urothelial Cancer Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
PD-1/PD-L1 Checkpoint Inhibitors Market by Product (Atezolizumab, Cemiplimab, Durvalumab), Indication (Hodgkin Lymphoma, Melanoma, Non Small Cell Lung Cancer), End User, Line of Therapy, Distribution Channel - Global Forecast 2025-2030 - Product Image

PD-1/PD-L1 Checkpoint Inhibitors Market by Product (Atezolizumab, Cemiplimab, Durvalumab), Indication (Hodgkin Lymphoma, Melanoma, Non Small Cell Lung Cancer), End User, Line of Therapy, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 193 Pages
  • Global
From
Antibody Drug Conjugate - Competitive Landscape, 2025 - Product Image

Antibody Drug Conjugate - Competitive Landscape, 2025

  • Report
  • 450 Pages
  • Global
From
Global Antibody Drug Conjugates Market - 2025-2035: Focus on Product, Application, Target, Payload Type, Linker Type, Linker Technology, and Geography - Product Image

Global Antibody Drug Conjugates Market - 2025-2035: Focus on Product, Application, Target, Payload Type, Linker Type, Linker Technology, and Geography

  • Report
  • Global
From

About the Urothelial Cell Carcinoma Drug Market

Urothelial Cell Carcinoma (UCC) is a type of cancer that affects the cells that line the urinary tract. Oncology drugs are used to treat UCC, and the UCC drug market is a subset of the larger oncology drug market. UCC drugs are typically divided into two categories: targeted therapies and immunotherapies. Targeted therapies are designed to target specific molecules or pathways that are involved in the growth and spread of cancer cells. Immunotherapies are designed to stimulate the body's own immune system to fight cancer cells. The UCC drug market is highly competitive, with many companies developing and marketing drugs for the treatment of UCC. Some of the major players in the market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, and Roche. These companies are actively researching and developing new drugs to treat UCC, as well as marketing existing drugs to treat the disease. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.